188 related articles for article (PubMed ID: 35586877)
1. Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.
Gan M; Zhang C; Qiu L; Wang Y; Bao H; Yu R; Liu R; Wu X; Shao Y; Hou P; Fei Z
Cancer Med; 2022 Nov; 11(21):4070-4078. PubMed ID: 35586877
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas.
Zhang Q; Yang Y; You X; Ju Y; Zhang Q; Sun T; Liu W
Front Oncol; 2023; 13():1173275. PubMed ID: 37546405
[TBL] [Abstract][Full Text] [Related]
3. Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy.
Lucchesi C; Khalifa E; Laizet Y; Soubeyran I; Mathoulin-Pelissier S; Chomienne C; Italiano A
JAMA Oncol; 2018 Oct; 4(10):1398-1404. PubMed ID: 29801054
[TBL] [Abstract][Full Text] [Related]
4. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
5. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
6. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
7. Next frontiers in systemic therapy for soft tissue sarcoma.
Yen CC; Chen TW
Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
[TBL] [Abstract][Full Text] [Related]
8. Next Generation Sequencing Reveals Pathogenic and Actionable Genetic Alterations of Soft Tissue Sarcoma in Chinese Patients: A Single Center Experience.
Jin G; Wang C; Jia D; Qian W; Yin C; Wang D; Yang Q; Li T; Zheng A
Technol Cancer Res Treat; 2021; 20():15330338211068964. PubMed ID: 34939467
[No Abstract] [Full Text] [Related]
9. The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy.
Xu LB; Zhao ZG; Xu SF; Zhang XX; Liu T; Jing CY; Zhang SG; Yu SJ
Int J Biol Markers; 2020 Sep; 35(3):14-22. PubMed ID: 32520634
[TBL] [Abstract][Full Text] [Related]
10. A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.
Bui NQ; Przybyl J; Trabucco SE; Frampton G; Hastie T; van de Rijn M; Ganjoo KN
Clin Sarcoma Res; 2019; 9():12. PubMed ID: 31528332
[TBL] [Abstract][Full Text] [Related]
11. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2023 May; 23(5):495-502. PubMed ID: 37017995
[TBL] [Abstract][Full Text] [Related]
12. Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets.
Kim J; Kim JH; Kang HG; Park SY; Yu JY; Lee EY; Oh SE; Kim YH; Yun T; Park C; Cho SY; You HJ
BMC Med Genet; 2018 Dec; 19(Suppl 1):216. PubMed ID: 30598078
[TBL] [Abstract][Full Text] [Related]
13. The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications.
Denu RA; Moyers JT; Gouda MA; Conley AP; Lazar AJ; Subbiah V
Clin Cancer Res; 2023 Nov; 29(22):4669-4678. PubMed ID: 37643131
[TBL] [Abstract][Full Text] [Related]
14. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract][Full Text] [Related]
15. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.
Elkrief A; Alcindor T
Curr Oncol; 2020 Feb; 27(Suppl 1):34-40. PubMed ID: 32174756
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.
Cote GM; He J; Choy E
Oncologist; 2018 Feb; 23(2):234-242. PubMed ID: 28860410
[TBL] [Abstract][Full Text] [Related]
18. Future directions in soft tissue sarcoma treatment.
Hall F; Villalobos V; Wilky B
Curr Probl Cancer; 2019 Aug; 43(4):300-307. PubMed ID: 31229264
[TBL] [Abstract][Full Text] [Related]
19. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
20. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
